Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Acadia Pharmaceuticals Inc.

< Previous 1 2 3 4 5 Next >
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.